In this article for Life Sciences Intellectual Property Review, Morgan Lewis partners Nathan Smith and Christopher Bright report that the role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked.
Read the full Life Sciences Intellectual Property Review article >>